Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

Nature Biotechnology

Volumn 17, Issue 6, 1999, Pages 555-561

  Sturniolo, Tiziana ^a   Bono, Elisa ^a   Ding, Jiayi ^b   Raddrizzani, Laura ^b   Tuereci, Oezlem ^c   Sahin, Ugur ^c   Braxenthaler, Michael ^b   Gallazzi, Fabio ^a   Protti, Maria Pia ^d   Sinigaglia, Francesco ^a   Hammer, Juergen ^a,b  

^a ROCHE MILANO RICERCHE   (Italy)

^b Hoffman La Roche ^*  (United States)

^c SAARLAND UNIVERSITY   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

DNA microarrays; Epitope prediction; Genomics; HLA matrix; Tumor immunology

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; HLA DR3 ANTIGEN; VACCINE;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; DATA BASE; GENE EXPRESSION; HLA SYSTEM; LIGAND BINDING; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; TISSUE SPECIFICITY;

ALLELES; AMINO ACID SEQUENCE; DATABASE MANAGEMENT SYSTEMS; DNA; EPITOPES; HLA-DR ANTIGENS; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 0033021020     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/9858     Document Type: Article

References (36)

1. Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-299 (1994).
2. Topalian, S.L. MHC class II restricted tumor antigens and the role of CD4 T cells in cancer immunotherapy. Curr. Opin. Immunol. 6, 741-745 (1994).
3. Stern, L.J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an Influenza virus peptide. Nature 368, 215-221 (1994).
4. Brown, J.H. et al. The three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33-39 (1993).
5. Ghosh, P., Amaya, M., Mellins, E. & Wiley, D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462 (1995).
6. Dessen, A., Lawrence, M.C., Cupo, S., Zaller, D.M. & Wiley, D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagene II. Immunity 7, 473-481 (1997).
7. Sinigaglia, F. & Hammer, J. Defining rules for the peptide-MHC class II interaction. Curr Opin. Immunol. 6, 52-56 (1994).
8. Hammer, J. et al. Precise prediction of major histocompatibility complex class II peptide interaction based on peptide side chain scanning. J. Exp. Med. 180, 2353-2358 (1994).
9. Marshall, K.W. et al. Prediction of peptide affinity to HLA DRB1*0401. J. Immunol. 154, 5927-5933 (1995).
10. Brusic, V., Rudy, G., Honeyman, G., Hammer, J. & Harrison, L. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14, 121-30 (1998).
11. Sette, A. et al. Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 328, 395-399 (1987).
12. Hammer, J., Sturniolo, T. & Sinigaglia, F. HLA class II peptide binding specificity and autoimmunity. Adv Immunol 66, 67-100 (1997).
13. Hammer, J. & Sinigaglia, F. in MHC Vol. 2, Vol. 181 (eds Fernandez, N. & Butcher, G.) 197-228 (Oxford Univ. Press, New York, 1998).
14. Hammer, J. New methods to predict MHC-binding sequences within protein antigens. Curr. Opin. Immunol. 7, 263-269 (1995).
15. Marsh, S.G.E. Nomenclature for factors of the HLA system, update January 1998. Tissue Antigens 51, 582-583 (1998).
16. Lockhart, D.J. et al. Expression monitoring by hybridization to high-density oligonucleotide arrays [see comments]. Nat. Biotechnol. 14, 1675-1680 (1996).
17. Wodicka, L., Dong, H., Mittmann, M., Ho, M.H. & Lockhart, D.J. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15, 1359-1367 (1997).
18. Gross, D.M. et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 281, 703-706 (1998).
19. Hammer, J. et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181, 1847-1855 (1995).
20. Tsuji, K., Aizawa, M. & Sasazuki, T. HLA 1991; Proceedings of the eleventh international histocompatibility workshop and conference (Oxford Univ. Press, New York, 1992).
21. Manici, S. et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 189, 871-876 (1999).
22. Topalian, S.L. et al. Melanoma-specific CD4 T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183, 1965-1971 (1996).
23. Hammer, J., Takacs, B. & Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176, 1007-1013 (1992).
24. Hammer, J. et al. Promiscuous and allele-specific anchors in HLA-DR binding peptides. Cell 74, 197-203 (1993).
25. Rammensee, H.G., Bachmann, J., Emmerich, N. & Stevanovic, S. SYFPEITHI: an internet database for MHC ligands and peptide motifs (access via http:/www.unituebingen.de/uni/kxi/). (data extracted in 4Q, 1998).
26. Blackwell, J.M. Parasite genome analysis. Progress in the Leishmania genome project. Trans. R. Soc. Trop. Med. Hyg. 91, 107-110 (1997).
27. Collins, F.S. et al. New goals for the U.S. Human Genome Project: 1998-2003. Science 282, 682-689 (1988).
28. Harwood, C.R. & Wipat, A. Sequencing and functional analysis of the genome of Bacillus subtilis strain 168. FEBS Lett. 389, 84-87 (1996).
29. Degrave, W., Levin, M.J., da Silveira, J.F. & Morel, C.M. Parasite genome projects and the Trypanosoma cruzi genome initiative. Mem. Inst. Oswaldo Cruz 92, 859-862 (1997).
30. Adams, M.D. et al. Sequence identification of 2,375 human brain genes [see comments]. Nature 355, 632-634 (1992).
31. Adams, M.D. et al. Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252, 1651-1656 (1991).
32. Ossendorp, F., Mengede, E., Camps, M., Filius, R. & Melief, C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693-702 (1998).
33. Sahin, U., Türeci, Ö. & Pfreundschuh, M. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709-716 (1997).
34. Raddrizzani, L. et al. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J. Immunol. 159, 703-711 (1997).
35. Panina-Bordignon, P. et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19, 2237-2242 (1989).
36. Ben-Mahrez, K., Thierry, D., Sorokine, I., Danna-Muller, A. & Kohiyama, M. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br. J. Cancer 57, 529-534 (1988).